MEDICINES FOR EUROPE

Tweet this page
<
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 13 May 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

500,000€ - 599,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

4 Fte (8)

Lobbyists with EP accreditation

4

High-level Commission meetings

83

Lobbying Costs over the years

  • Info

    MEDICINES FOR EUROPE   (-)

    EU Transparency Register

    48325781850-28 First registered on 16 Jun 2009

    Goals / Remit

    Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value added medicines industries. As a leading partner for better healthcare, we aim to increase the health and wellbeing of all Europeans through better access to high quality medicines. Medicines for Europe members’ portfolio cover 80% of therapy areas, and in so doing, safeguards the sustainability of Europe’s healthcare systems for future generations.

    Main EU files targeted

    Medicines for Europe plays an important consultative part in European healthcare policy-making and provides key educational role for its members. Medicines for Europe and its members work with European national governments and the EU institutions to develop sustainable solutions for pharmaceutical care and to increase Europe’s competitive strength in the global pharmaceutical medicines market.
    Medicines for Europe is engaged to work on a variety of EU pharmaceutical policies and legislative proposals, which include, but is not limited to:
    The implementation of the pharmaceutical and IP strategies; The implementation of the SPC Manufacturing Waiver, which was introduced in July 2019; the broad review of the pharmaceutical incentives (e.g. Bolar, variations, orphan and paediatric medicines, etc.); the review of the SPC legislation (i.e. Unitary SPC, SPC legal review, etc.) and the patent system; the industrial policy to stimulate more investments in Active Pharmaceutical Ingredients’ production in Europe and critical medicines ; the possible review of the Transparency Directive on pharmaceutical; the rules on pharmaceuticals’ public procurement; all competition policies aimed to ensure off-patent medicines timely access to the market; all policies related to shortages of medicines; the policy discussions around pharmaceuticals in the environment; education and policies regarding biosimilar medicines; the development of information and awareness around value added medicines; the EMA work around generic and biosimilar medicines; the work of the Pharmaceutical Committee more generally; trade agenda; digital agenda.

    Address

    Head Office
    RUE D'ARLON, 50
    BRUSSELS 1000
    BELGIUM
    EU Office
    RUE D'ARLON, 50
    BRUSSELS 1000
    BELGIUM

    Website

  • People

    Total lobbyists declared

    8

    Employment timeLobbyists
    100%2
    75%1
    25%5

    Lobbyists (Full time equivalent)

    4

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    4 accreditations were / are live (in bold) for the selected state of 28 May 2024

    Name Start date End Date
    Luca PROSDOCIMO 18 May 2023 18 May 2024
    Gabriele NICOTRA 19 Jan 2024 17 Jan 2025
    Raluca RADU 27 Jul 2023 26 Jul 2024
    Giuliana PENNISI 14 Sep 2023 13 Sep 2024
    Sophie DAGENS 27 Jul 2023 26 Jul 2024
    Mr Adrian van den Hoven 10 Mar 2023 11 Mar 2024
    Ms Beata Katarzyna STEPNIEWSKA-KOOLEN 04 Mar 2023 11 Mar 2024
    Mr Sergio NAPOLITANO 21 Jan 2023 20 Jan 2024
    Gabriele NICOTRA 13 Jan 2023 13 Jan 2024
    Giuliana PENNISI 15 Sep 2022 14 Sep 2023
    Luca PROSDOCIMO 24 May 2022 18 May 2023
    Gabriele NICOTRA 21 Apr 2022 01 Jan 2023
    Mr Andrea PUCCI 20 Nov 2021 11 Sep 2022
    Maja SERCIC 18 Nov 2021 18 Nov 2022
    Riccardo BONANNI 29 Oct 2021 01 Mar 2022
    Giuliana PENNISI 13 Sep 2021 14 Sep 2022
    Mr Sergio NAPOLITANO 24 Sep 2019 01 Oct 2020
    Giuliana PENNISI 13 Jul 2019 11 Jul 2020
    Mr Sergio NAPOLITANO 20 Sep 2018 20 Sep 2019
    Mr Andrea PUCCI 12 Sep 2018 01 Oct 2019
    Giuliana PENNISI 22 Jun 2018 22 Jun 2019
    Giuliana PENNISI 18 May 2017 17 May 2018
    Julie Chauvet 02 Apr 2016 22 Feb 2017
    Julie Chauvet 26 Mar 2015 24 Mar 2016
    Julie Chauvet 28 Mar 2014 26 Mar 2015
    Julie Chauvet 20 Mar 2013 19 Mar 2014
    Julie Chauvet 04 Apr 2012 20 Mar 2013

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Trade and business associations

  • Networking

    Affiliation

    • Consultative status with World Intellectual Property Organization (WIPO)
    • Founding Member International Generic and Biosimilar Pharmaceutical Alliance (IGBA)
    • Member Federation of European and International Associations Established in Belgium (FAIB)

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    500,000€ - 599,999€

    Major contributions in closed year

    TypeNameAmount
    Grant EU, Horizon Europe 72,821€

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    500,000€ - 599,999€

    Other financial info

    The grants indicated above are part of a total grant of 208.062 Euro that is spread over a 5 year period. While in the financial year 1/2023-12/2023 there was no grant (considered 'current financial year' above), on 4 February 2024 Medicines for Europe received a grant of 20 505,91 EUR, still part of the same total grant.

  • EU Structures

    Groups (European Commission)

    Antimicrobial Resistance One Health Network#E03853#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3853 #MEMBER #C#IndustryMedical Device Coordination Group#X03565#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3565 #OBSERVER #C#Industry06 - Borderline and Classification (B&C)#X03565/8#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=100603 #OBSERVER #C#IndustryEXPERT GROUP FOR THE IMPLEMENTATION OF THE EU ANTI-TORTURE REGULATION (ATR) #E03762#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3762 #MEMBER #C#Industry#SMEs10 - International Matters#X03565/11#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=100607 #OBSERVER #C#Industry

    Groups (European Parliament)

    N/A

    Communication activities

    List of activities
    • conferences, webinars, communication campaigns and workshops organisation
    • membership services and publications (EU Members Brief and highlights)
    • scientific, legal and economic assessment reports
    • EU and International representation

    Other activities

    None declared

  • Meetings

    Meetings

    83 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard